PA8599701A1 - Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr - Google Patents

Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr

Info

Publication number
PA8599701A1
PA8599701A1 PA20048599701A PA8599701A PA8599701A1 PA 8599701 A1 PA8599701 A1 PA 8599701A1 PA 20048599701 A PA20048599701 A PA 20048599701A PA 8599701 A PA8599701 A PA 8599701A PA 8599701 A1 PA8599701 A1 PA 8599701A1
Authority
PA
Panama
Prior art keywords
dosage forms
treatment procedures
vegfr inhibitors
dosage
forms
Prior art date
Application number
PA20048599701A
Other languages
English (en)
Inventor
James Lawrence Freddo
Dana Hu-Lowe
Yazdi Kersi Pithvala
Heidi Marie Steinfeldt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8599701A1 publication Critical patent/PA8599701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

LA INVENCION PROPORCIONA FORMAS DE DOSIFICACION DE UN COMPUESTO DE FORMULA 1: O SALES, SOLVATOS O PRECURSORES FARMACOLOGICOS FARMACEUTICAMENTE ACEPTABLES DEL MISMO. LA INVENCION PROPORCIONA ADEMAS PROCEDIMIENTOS DE TRATAMIENTO DEL CRECIMIENTO CELULAR ANORMAL, TAL COMO CANCERES, MEDIANTE LA ADMINISTRACION DE FORMAS DE DOSIFICACION A UN MAMIFERO.
PA20048599701A 2003-04-03 2004-04-02 Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr PA8599701A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46069503P 2003-04-03 2003-04-03
US49177103P 2003-07-31 2003-07-31

Publications (1)

Publication Number Publication Date
PA8599701A1 true PA8599701A1 (es) 2004-11-26

Family

ID=33135143

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048599701A PA8599701A1 (es) 2003-04-03 2004-04-02 Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr

Country Status (16)

Country Link
US (1) US20040224988A1 (es)
EP (1) EP1613320A1 (es)
JP (1) JP2006522087A (es)
KR (1) KR20050119671A (es)
AR (1) AR043822A1 (es)
AU (1) AU2004226586B2 (es)
BR (1) BRPI0409230A (es)
CA (1) CA2520932A1 (es)
MX (1) MXPA05009303A (es)
NL (1) NL1025873C2 (es)
NO (1) NO20055143L (es)
PA (1) PA8599701A1 (es)
RU (2) RU2341263C2 (es)
TW (1) TW200423933A (es)
UY (1) UY28255A1 (es)
WO (1) WO2004087152A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530654A (ja) * 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
RU2007116107A (ru) * 2004-11-02 2008-11-10 Пфайзер Инк. (US) Способы получения индазольных соединений
ES2432091T5 (es) 2005-03-25 2022-03-18 Gitr Inc Moléculas de unión GITR y usos de las mismas
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
ES2591281T3 (es) 2007-07-12 2016-11-25 Gitr, Inc. Terapias de combinación que emplean moléculas de enlazamiento a GITR
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
AU2012313885A1 (en) 2011-09-30 2014-03-13 Pfizer Inc. Pharmaceutical compositions of N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide
CN103917234A (zh) 2011-11-11 2014-07-09 辉瑞大药厂 用于治疗慢性骨髓性白血病的n-甲基-2-〔3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基〕-苯甲酰胺
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
ES2899457T3 (es) 2014-02-04 2022-03-11 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
JP6414727B2 (ja) * 2014-04-01 2018-10-31 公益財団法人ヒューマンサイエンス振興財団 関節疾患の治療予防剤
CN104013589A (zh) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 一种阿西替尼口腔崩解片及其制备方法
JP2017530950A (ja) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
CN112263677A (zh) 2015-02-26 2021-01-26 默克专利股份公司 用于治疗癌症的pd-1/pd-l1抑制剂
US10869924B2 (en) 2015-06-16 2020-12-22 Merck Patent Gmbh PD-L1 antagonist combination treatments
AU2017217677A1 (en) 2016-02-08 2018-07-26 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
JP2019530704A (ja) 2016-10-06 2019-10-24 ファイザー・インコーポレイテッド がんの処置のためのアベルマブの投与レジメン
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2023166418A2 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334255D1 (de) * 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5339184A (en) * 1992-06-15 1994-08-16 Gte Laboratories Incorporated Fiber optic antenna remoting for multi-sector cell sites
US5459607A (en) * 1993-04-19 1995-10-17 C-Cor/Comlux, Inc. Synchronous optical digital transmission system and method
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) * 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3588984B2 (ja) * 1997-08-20 2004-11-17 Ｋｄｄｉ株式会社 光パワー計測システム並びにそのための端局及び中継器
GB2332603B (en) * 1997-12-22 2000-07-19 Lsi Logic Corp Improvements relating to multidirectional communication systems
US6529303B1 (en) * 1998-03-05 2003-03-04 Kestrel Solutions, Inc. Optical communications networks utilizing frequency division multiplexing
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US6643470B1 (en) * 1999-10-01 2003-11-04 Matsushita Electric Industrial Co., Ltd. FM signal converter, FM signal optical transmitter and FM signal optical receiver

Also Published As

Publication number Publication date
AU2004226586B2 (en) 2008-12-11
NO20055143D0 (no) 2005-11-02
NO20055143L (no) 2006-01-03
US20040224988A1 (en) 2004-11-11
RU2005128791A (ru) 2006-05-10
JP2006522087A (ja) 2006-09-28
WO2004087152A1 (en) 2004-10-14
NL1025873A1 (nl) 2004-10-05
MXPA05009303A (es) 2005-10-05
CA2520932A1 (en) 2004-10-14
AR043822A1 (es) 2005-08-17
EP1613320A1 (en) 2006-01-11
TW200423933A (en) 2004-11-16
BRPI0409230A (pt) 2006-03-28
NL1025873C2 (nl) 2006-02-14
KR20050119671A (ko) 2005-12-21
AU2004226586A1 (en) 2004-10-14
RU2341263C2 (ru) 2008-12-20
UY28255A1 (es) 2004-11-30
RU2008122358A (ru) 2009-12-10

Similar Documents

Publication Publication Date Title
PA8599701A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del vegfr
PA8680701A1 (es) Derivados de oxindol
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
ATE433447T1 (de) Pyrimiidinverbindungen
UY28736A1 (es) Derivados de quinazolina
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
ECSP055726A (es) Composición farmacéutica estabilizada que contiene excipientes básicos
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
SE0202539D0 (sv) Compounds
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
MX2007013624A (es) Inhibidores de proteina cinasa.
GEP20125538B (en) 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
WO2007120333A3 (en) Tetracyclic kinase inhibitors
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
MXPA04004606A (es) Venenos de topoisomerasa solubilizados.
CR7195A (es) Nuevos derivados de oxazolidinonas como antibacterianos
DK1594885T3 (da) Lægemiddel til vækstinhibering af tumorer